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Abstract
Anaplastic thyroid cancer (ATC) is a rare and lethal human malignancy with no known effec-
tive therapies in the majority of cases. Despite the use of conventional treatments such as
chemotherapy, radiation and surgical resection, this disease remains almost universally
fatal. In the present study, we identified the JAK2 inhibitor Lestaurtinib as a potent com-
pound when testing against 13 ATC cell lines. Lestaurtinib demonstrated a potent antiproli-
ferative effect in vitro at nanomolar concentrations. Furthermore, Lestaurtinib impeded cell
migration and the ability to form colonies from single cells using scratch-wound and colony
formation assays, respectively. Flow cytometry was used for cell cycle analysis following
drug treatment and demonstrated arrest at the G2/M phase of the cell cycle, indicative of a
cytostatic effect. In vivo studies using the chick chorioallantoic membrane xenograft models
demonstrated that treatment with Lestaurtinib resulted in a significant decrease in endpoint
tumor volume and vascularity using power Doppler ultrasound imaging. Overall, this study
provides evidence that Lestaurtinib is a potent antiproliferative agent with potential antian-
giogenic activity that warrants further investigation as a targeted therapy for ATC.
Introduction
Thyroid cancer is the most common endocrine malignancy[1]. Well-differentiated thyroid
cancers make up the majority of thyroid cancers and have an excellent prognosis[2]. In con-
trast, anaplastic thyroid cancer (ATC) is a rare type of undifferentiated thyroid cancer that
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makes up approximately 1% of thyroid cancer cases and is arguably the most lethal human
malignancy[3–5]. Patients diagnosed with ATC typically present with a rapidly expanding
neck mass resulting in airway and esophageal obstruction, and distant metastases[6,7]. Despite
the aggressive use of chemotherapy, radiation and surgical resection, the outcomes for patients
with ATC remain dismal, with a mean survival of only 6 months[6,8]. While there have been
studies to date with the aim of understanding the molecular pathogenesis of disease, it is evi-
dent that ATC is still very poorly understood[9–11].
Presently, there are no effective therapies for patients diagnosed with ATC and therefore,
the use of targeted agents directed against specific genetic alterations and signaling pathways
remains an attractive cancer treatment strategy. Small-molecule tyrosine kinase inhibitors rep-
resent a molecularly-precise method of cancer treatment that can be used to target specific sig-
naling pathways and produce an antiproliferative effect[12,13]. Indeed, kinase inhibitors are
undergoing active investigation in every major cancer type and have been shown to provide
meaningful therapeutic responses in recurrent and metastatic diseases, with increased cure
rates when administered concurrently or in the adjuvant setting with surgery or radiation[14–
16]. While a small number of targeted agents have been tested in patients with ATC, there are
currently no therapies that have been approved for routine treatment of ATC[17].
To begin to fill the gap in our understanding of this disease and how it can be treated, we
screened 13 ATC cell lines and identified Lestaurtinib as a highly potent agent with nanomolar
potency. Efficacy of Lestaurtinib was further validated both in vitro and in vivo using the chick
chorioallantoic membrane (CAM) xenograft model.
Materials and methods
Cell lines and culture conditions
THJ-11T, -16T, -21T, and -29T were all obtained from Dr. John Copland of the Mayo Clinic.
U-Hth7, U-HTh74cl.7, C643, and SW1736 cell lines were obtained from Dr. Nils Erik Heldin
(University of Uppsala, Sweden). Cell lines 8505C, ASH3 and KMH2 were all purchased from
the Japanese Collection of Research of Bioresources Cell Bank (JCRB). Lastly, BHT-101 and
CAL62 were both purchased from the DSMZ Cell Bank.
THJ-11T, -16T, -21T, and -29T cell lines were cultured in RPMI 1640 media supplemented
with 10% FBS (GIBCO), 1x non-essential amino acids (Wisent), 1 mM sodium pyruvate
(Wisent), penicillin (100 μg/mL) and streptomycin (100 μg/mL) (Invitrogen). U-Hth7,
U-HTh74cl.7, C643, SW1736 and 8505C cell lines were cultured in EMEM media supple-
mented with 10% FBS (GIBCO), penicillin (100 μg/mL) and streptomycin (100 μg/mL) (Invi-
trogen). ASH3 and KMH2 cell lines were cultured in a 1:1 mixture of DMEM and RPMI 1640,
which was supplemented with 10% heat-inactivated FBS (GIBCO), penicillin (100 μg/mL) and
streptomycin (100 μg/mL) (Invitrogen). BHT-101 and CAL62 cell lines were cultured in
DMEM supplemented with 10% heat-inactivated FBS (GIBCO), 1% human serum (Wisent),
penicillin (100 μg/mL) and streptomycin (100 μg/mL) (Invitrogen).
Short tandem repeat (STR) profiling of ATC cell lines
DNA was extracted from cultured cells using the AllPrep DNA/RNA/Protein kit (Qiagen),
using the instructions provided by the manufacturer. A total of 100 ng of DNA per cell line
was analyzed by short tandem repeat (STR) profiling at The Center for Applied Genomics
(TCAG, Toronto, Canada). Cell lines were genotyped with 16 selected markers (including the
8 Combined DNA Index System (CODIS)) core STR loci, employed by the American Type
Culture Collection (ATCC) and confirmed against published information (S1 Table).
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Drug selection
A Beckman BioMek FX liquid handler was used to dispense cells into 384-well culture plates
(Corning, NY, USA) at a density of 12,000 cells/ml in a total volume of 50 μl/well. Seeded cells
were incubated for 24 hours (h) at 37˚C, 5% CO2. Lestaurtinib was initially assembled as 1mM
stocks in 100% DMSO and pinned (200 nL) into wells 24 h post-seeding. Drug testing was car-
ried out using six different concentrations ranging between 0.16 and 4 μM (final concentra-
tions) and applied to the 13 cell lines (2 biological replicates). Negative controls consisted of
wells in the same 384-well culture plate containing cells that were treated with 0.4% DMSO
vehicle alone. Wells containing media only were used as a measure to determine assay back-
ground noise. To measure the percent inhibition of growth, 5 μl/well of AlamarBlue (Invitro-
gen) was added to each well after a 48 h incubation period of the cells with the Lestaurtinib.
After the addition of AlamarBlue, cells were incubated for 4 h at 37˚C and then fluorescence
intensity was measured in a PHERAstar microplate reader (BMG LABTECH) equipped with
535nm excitation and 590 nm emission filters. Drug testing was completed in duplicate.
Raw data were loaded into the R statistical environment (v3.2.1). Normalized absorbance
values were obtained by contrasting experimental absorbance values with those from vehicle
control (DMSO-treated) cells. The half-maximal inhibitory concentrations (IC50 in μM) were
calculated using the nplr package (v0.1–4). Similarly, the activity area (AA) was calculated as
the area under the percent (%) inhibition curve using the nplr (v0.1–4) package for R. Results
were filtered to remove those with poorly fitted models (R-squared < 0.9). Cell lines were clas-
sified as resistant to a compound if absorbance increased or remained constant over time; like-
wise, classification as sensitive required an IC50 within the range examined (0.16–4 μM) with
the 85% confidence interval ± 2 μM. Consensus clustering using the ConsensusClusterPlus.
custom (v1.8.1) package for R was used to find groups of cell lines with similar response pat-
terns (based on activity area).
Reagents
The tyrosine kinase inhibitor Lestaurtinib (CEP-701) was purchased from Tocris (Cephalon
Inc.). Lestaurtinib was dissolved in dimethyl sulfoxide (DMSO) as a 10-mM stock. Subsequent
serial dilutions were performed for specific concentrations as shown in the Results section.
Growth curves
Cells were seeded at a density of 2,400 cells/well into a 96-well plate and incubated overnight.
After 24 h, cells were treated with 0.5 and 4.0 μM concentrations of Lestaurtinib. Cells were
incubated with PrestoBlue (Thermo Fisher Scientific) for 1 h at 37˚C and plates were read at 0,
24, 48 and 72 h after the addition of the drug. Fluorescence readings were completed using a
BioTek Synergy Microplate Reader with 560nm excitation and 590nm emission wavelengths.
Three technical replicates were used for each concentration tested. A Student’s unpaired, two-
tail t-test was used for statistical analysis using Prism 7 Graphpad Software, where compari-
sons were made between treated and untreated samples for each timepoint. P values < 0.05
were considered to represent statistically significant differences. Statistical analysis is displayed
for the 72 h timepoint when compared to the control at the same timepoint.
Dose-response curves
Cells (KMH2, CAL62 and THJ-21T) were seeded at a density of 2,400 cells/well into a 96-well
plate and incubated overnight. After a 24 h incubation period, cells were treated with increas-
ing concentrations of Lestaurtinib (0.06 to 4.0 μM) for 72 h. After 72 h, cells were incubated
Lestaurtinib as a potent inhibitor of ATC
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with PrestoBlue for 1 h at 37˚C. The same procedure was completed using the normal cell
line, WI-38, with increasing concentrations of Lestaurtinib (0.125 to 2.0 μM) for 72 h. For
ATC cell lines, two biological replicates were completed with 3 technical replicates for
each concentration. For WI-38, one biological replicate was completed with 3 technical
replicates for each concentration. Fluorescence readings were completed using a BioTek
Synergy Microplate Reader with 560nm excitation and 590nm emission wavelengths.
These values were normalized to the untreated controls and the average viability for each
concentration was calculated. In order to determine the half-maximal inhibitory concen-
tration (IC50), the normalized relative fluorescence values of the Lestaurtinib-treated sam-
ples were calculated as a percentage of the mean relative fluorescence units of the
untreated, control samples. Drug concentrations were transformed to a logarithmic scale
and IC50 values were calculated using non-linear regression (curve fit). Analysis was com-
pleted using Prism 7 Graphpad Software.
Immunoblotting
Cells were seeded at a density of 200,000 cells/well into 6-well plates and incubated overnight.
For treatments, cells were treated with DMSO-only (vehicle) or Lestaurtinib concentrations of
0.125, 0.25, 0.5, 1.0, 2.0 and 4.0 μM for 24 h. Staurosporine-treated cells (5 μM, 3 h) were used
as a positive control for apoptosis. Cells were lysed, and a Bradford assay was performed to
determine the protein concentration of the whole cell lysates using the Bio-rad Protein Assay
Dye Reagent (Bio-Rad). NuPAGE Novex 4–12% Bis-Tris Gel (ThermoFisher Scientific) was
used for protein separation with 20 μg of total protein loaded per well and run at 200V (1
hour). Novex Sharp Standard protein ladder was used to determine the mass of products. A
PVDF blotting membrane (GE Healthcare) was used for protein transfer at 14V (1 hour).
Membranes were blocked using 5% bovine serum albumin (Sigma-Aldrich). Primary antibod-
ies were prepared according to the manufacturer and used overnight at 4˚C with constant,
mild agitation. Endogenous JAK2 (Cat no. 3230P), phospho-JAK2 (p-JAK2; Cat no. 3776S),
phospho-STAT5 (p-STAT5; Cat no. 9351S) and α-tubulin (Cat no. 2125S) antibodies were
obtained from Cell Signaling Technology. Endogenous STAT5 (Cat no. sc-835) was obtained
from Santa Cruz Biotechnology. Mouse anti-human PARP (Cat no. 556494) was obtained
from BD Pharminogen. Secondary antibodies were diluted 1:5000. Detection of target proteins
was performed using Luminata Forte Western HRP substrate (EMD Millipore). Detection of
α-tubulin was used as a loading control.
Colony formation assay
Cells (CAL62) were seeded into 24-well plates at a density of 1,000 cells/well. After 24 h, cells
were treated with 0, .125, .25, .50, 1.0, 2.0 and 4.0 μM concentrations of Lestaurtinib, with 1
biological replicate, and incubated at 37˚C for 7 days with Lestaurtinib-containing media
being replaced every 3 days. Cells were washed with PBS and fixed with cold 100% methanol
for 15 minutes prior to staining with 0.5% crystal violet in 10% methanol/1x PBS for 10 min-
utes. Brightfield microscopy was used for quantification of colonies, which were defined as
being�50 cells. A total of 3 representative fields per well were counted for colonies based on
the above cell number parameter. This was completed for each concentration of Lestaurtinib
tested and the number of colonies were totaled for each concentration. A Student’s unpaired,
two-tail t-test was used for statistical analysis using Prism 7 Graphpad Software. Samples were
compared relative to the untreated control and p values < 0.05 were considered to represent
statistically significant differences in colony formation.
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Cell motility assay
Cells (CAL62) were seeded into 6-well plates at a density of 150,000 cells/well and incu-
bated until 90% confluence. After 24 h, cells were washed with PBS and scratched through
the middle in a straight line using a sterile P1000 pipette tip. Immediately after the scratch,
wells were either exposed to media containing the vehicle (DMSO) or media containing
Lestaurtinib at 0.5- or 4.0 μM. The migration of cells from the outer edge of the scratch
towards the center was measured at 0, 4 and 24 h. A total of 10 measurements over the
length of the scratch were taken for each timepoint to produce the mean scratch width
(pixels), for 3 replicates per time point. Means and standard errors were calculated and
normalized to the 0 h timepoint. A Student’s unpaired, two-tail t-test was used for statisti-
cal analysis using Prism 7 Graphpad Software and p values < 0.05 were considered statisti-
cally significant.
JAK2 knockout by CRISPR/Cas9
Two cell lines (KMH2 and CAL62) were used for CRISPR/Cas9 gene editing of JAK2. Cells of
each line were seeded at a density of 5 x 104 cells/well in a 24-well dish. Lentivirus expressing
Cas9 was added to cells at a multiplicity of infection (MOI) of 0.3. When integration had
occurred, blasticidin selection was used to kill untransduced cells, with a concentration that
was previously determined with kill curves for each cell line. Cas9 expression was confirmed
by Western blot analysis. The Cas9 (+) cell lines were then transduced with lentivirus carrying
a single guide RNA (sgRNA) against JAK2 (NM_004972, targets Exon19; Cat no. VSGH101
42-246580412; Dharmacon), a scrambled non-targeting control (negative control), or a
sgRNA against DNMT3B (positive control). Transduced cells were selected using puromycin
(using a concentration determined by kill curves for each cell line) and confirmed using west-
ern blot analysis probing for endogenous JAK2. Proliferation was compared between the non-
targeting CRISPR control and JAK2 knockout lines where cell lines were seeded in 96-well
plates at a density of 2,400 cells/well. After 72 h, PrestoBlue was added to wells and plates were
incubated for 1 h prior to fluorescence readings using a BioTek Synergy H4 Hybrid Microplate
Reader with 560nm excitation and 590nm emission wavelengths. Relative fluorescence units
were normalized to yield percent (%) proliferation compared to the non-targeting control.
Furthermore, we completed dose-response curves where CAL62 and KMH2:JAK2 knockout
(KO) cell lines were seeded into 96-well plates at a density of 2,400 cells/well. At 24 h post-
seeding, Lestaurtinib was added at a range of increasing concentrations (0.125–4 μM). After
72 h, PrestoBlue was added to wells and plates were read as mentioned above. A Student’s
unpaired, two-tail t-test was used for statistical analysis using Prism 7 Graphpad Software and
p values< 0.05 were considered statistically significant differences.
Live-dead cell assay
Cells (KMH2 and CAL62) were seeded at a density of 100,000 cells/well. After 24 h, cells were
either untreated or treated with 0.5 μM or 1 μM Lestaurtinib. Plates were incubated at 37˚C
for 24 h. Cells were then washed with PBS and trypsinized; 10 μl of resuspended cells were
combined with Trypan Blue (Sigma-Aldrich; Cat. T8154) at a 1:1 ratio for 10 minutes. Cells
were counted using a hemocytometer and Brightfield microscopy. The ratio of live-dead cells
was then calculated for each based on their exclusion of dye. The number of live cells per mL
were calculated and compared to the untreated control using a Student’s unpaired, two-tail
t-test. P values < 0.05 were considered to be statistically significant.
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Cell-cycle analysis
To determine the effects of Lestaurtinib on cell cycle distribution, we treated two ATC cell
lines (CAL62 and KMH2) with either DMSO-only or 4 μM Lestaurtinib for 24 h, with 3 bio-
logical replicates each. This concentration was chosen from the upper range of the high-
throughput drug screen, and both cell lines were picked due to their sensitivity as noted from
the IC50 analysis. Bromo-deoxyuridine (BrdU; GE Healthcare, Cat. RPN201) was added to cell
media and incubated in culture for 2 h prior to collection. Cell were trypsinized, collected and
washed 3 times with PBS prior to using 95% freezer-chilled ethanol to fix cells. Cells were per-
meabilized using 2N HCl/0.5% Triton X-100, followed by 0.1 M NaB4O7. Primary (Mouse
anti-BrdU primary antibody, 1:50; BD Biosciences lot. 347580) and secondary (FITC-conju-
gated rabbit anti-mouse secondary antibody, 1:25; Vector Laboratories Cat. FI-2000) antibod-
ies were added and incubated for 30 minutes for each step. Cell pellets were resuspended in
propidium iodide (PI; 10 mg/ml) and RNase A (0.25 mg/ml; Bioshop Canada Inc., Cat.
RNA675) and incubated overnight at 4˚C. The following day, cell cycle analysis using flow
cytometry was performed using a Beckman Coulter Inc, Cytomics FC500 flow cytometer with
at least 10,000 events that were counted per test. Statistical analysis was performed using a Stu-
dent’s unpaired, two-tail t-test to compare treated and untreated samples.
Antitumor activity studies in vivo
One million cells of the CAL62 cell line were combined with Matrigel matrix at a 1:1 ratio. Chick
embryos were used at 9 days post-fertilization. A small circle of filter paper was placed on an area
with small blood vessels of the chorioallantoic membrane to score the area for the onplant of cells.
A total volume of 10 μl, containing the 1:1 ratio of 5 μl 1 million cells: 5 μl Matrigel, was pipetted
over top of the scored area. Once the onplant of cells was complete, embryos were covered and
incubated for 2 days at 37˚C. Drug treatments were initiated 2 days post-onplant with either vehi-
cle (DMSO) (n = 11) or 4 μM Lestaurtinib (n = 19) and applied once daily for a 5-day duration.
Tumor volume was measured at the experimental endpoint using B-mode (anatomical) ultra-
sound imaging. Vascularity was measured at endpoint using power Doppler ultrasound imaging,
which estimates fractional vascular volume by displaying the ultrasound power reflected from
moving blood cells in detectable vessels, which are typically larger than 100 μm diameter.
All ultrasound measurements were performed using a Vevo 2100 high frequency imaging
system (VisualSonics Inc.). B-mode and power Doppler images were acquired using a 40 MHz
linear array (MS-550D, 40 μm axial resolution, 80 μm lateral resolution). The imaging field of
view was set to 10.00 mm (axial) by and 14.08 mm (lateral) with a Doppler color box sized to
completely enclose the largest cross-section of tumor. Three-dimensional volumetric images
were acquired using a linear stepper motor (VisualSonics Inc.) with a step size 0.076 mm and a
total step distance 7.98 mm.
Volumetric image reconstruction and analysis was performed using the supplied software
(Vevo 2100 Workstation, VisualSonics Inc.). Estimates of tumor volume were computed via
manual planimetry on reconstructed three-dimensional B-mode images. The fractional vascu-
lar blood volume in the tumor was calculated by summing the number of Doppler color voxels,
which correspond to regions with detected blood flow, within the segmented volume and
dividing by the total number of voxels in the volume to yield percent vascularity. This yields
the percentage tumor vascularity, which is normalized to the tumor volume.
Statistical analysis
A Student’s unpaired, two-tail t-test was performed where appropriate using Prism 7 Graph-
pad Software Macintosh Version (by Software MacKiev 1994–2014 GraphPad Software, Inc).
Lestaurtinib as a potent inhibitor of ATC
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P values< 0.05 were considered statistically significant. P values are defined as ns p> 0.05, �
represents p< 0.05, �� represents p< 0.01, and ��� represents p< 0.001.
Results
Lestaurtinib inhibits growth of ATC cell lines
We found Lestaurtinib, a JAK2 inhibitor, to be a highly potent agent across our cell line panel
with 11 out 13 cell lines having nanomolar IC50 values. The cell line KMH2 was the most sensi-
tive with a mean IC50 between both biological replicates of 0.21 ± 0.06 μM (Fig 1A and 1B).
CAL62 was the sixth most sensitive, falling into the middle of our cell line panel, with a mean
IC50 of 0.41 ± 0.001 μM (Fig 1A and 1B). THJ-21T was the most resistant cell line in our
panel, with a mean IC50 of 2.35 ± 0.42 μM (Fig 1A and 1B). Lestaurtinib potency was also
tested against the normal lung fibroblast cell line, WI-38, to measure how treatment with this
drug would affect a normal cell line. Using a concentration range of 0.125–2 μM Lestaurtinib,
we could not establish an IC50 for WI-38 because growth was not inhibited (Fig 1B).
We then sought to determine whether the measured sensitivity of ATC cell lines to Lestaur-
tinib could be explained by endogenous levels of JAK2 or its downstream target STAT5. Using
Western blot analysis, we noted that neither the most sensitive lines (KMH2, 8505C and BHT-
101) nor the most resistant lines (C643, ASH3 and THJ-21T), exhibited any correlation
between the expression levels of endogenous JAK2 or STAT5 and sensitivity to Lestaurtinib
treatment (S1 Fig). Given the high potency of Lestaurtinib and its’ potential as a therapeutic
agent in our cell line panel, we selected both KMH2 and CAL62 cell lines for in vitro and in
vivo validation studies.
To investigate whether Lestaurtinib was acting through the JAK2 pathway as predicted, we
treated CAL62 with increasing concentrations of Lestaurtinib for 24 h. Treatment with Les-
taurtinib did not result in a decrease of phospho-JAK2 (pJAK2) or endogenous JAK2; how-
ever, the downstream molecule STAT5 demonstrated a concentration-dependent decrease in
phosphorylation starting at 0.125 uM (pSTAT5), with a complete disappearance of pSTAT5
expression at 4 μM (Fig 1C). For these reasons, we chose to use concentrations of 4 μM in our
in vivo studies to determine the effects of inhibition of the JAK2 pathway with complete deple-
tion of pSTAT5 expression.
Lestaurtinib impaired colony formation and cell migration, in vitro
Normal (WI-38) and ATC (CAL62 and KMH2) cells were treated Lestaurtinib for a 24-hour
period. Following 24 h of treatment, a concentration of 0.5 μM Lestaurtinib showed fewer cells
with a rounder morphology in both CAL62 and KMH2 lines (Fig 2A). However, WI-38 cells
treated with 0.5 μM were not inhibited (Fig 2A).
We next evaluated the effect of Lestaurtinib treatment on cells using a colony formation
assay. Treatment of CAL62 with increasing concentrations of Lestaurtinib resulted in a signifi-
cant inhibition of colony formation at all concentrations in the range of 0.125 to 4.0 μM when
compared to the untreated control over a 7-day period (Fig 2B).
Previous studies identified a role for the JAK2-STAT pathway in cell migration[18–20],
thus if Lestaurtinib acted on the JAK2-STAT pathway then we sought to determine how Les-
taurtinib treatment would impact migration of CAL62 cells using a scratch-wound assay. At
both 4- and 24 h, there was a significant difference in normalized scratch width percentage
(%), where drug-treated scratches (0.5 and 4.0 μM) remained relatively open compared to the
control (Fig 2C).
Lestaurtinib as a potent inhibitor of ATC
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Lestaurtinib treatment induced an antiproliferative effect with knockout of
JAK2 in ATC cell lines
We used CRISPR/Cas9 technology to knockout JAK2 in CAL62 and KMH2 cells, which
would be expected to make the cells resistant to drug treatment. Complete knockout (KO) of
JAK2 protein expression was achieved in both cell lines (Fig 3A). Furthermore, we noted that
there was a decrease in STAT5 phosphorylation following JAK2 knockout, recapitulating one
of the effects of Lestaurtinib treatment (Fig 3A). We then looked at cellular proliferation and
found that the JAK2-edited CAL62 line exhibited a significant increase in cellular proliferation
Fig 1. Lestaurtinib is identified as a potent agent across a panel of 13 ATC cell lines. (A) Lestaurtinib was tested against 13 ATC cell lines, with 2
biological replicates per cell line. Cells were treated with Lestaurtinib for 48 h and readings were completed after incubation with AlamarBlue. Mean
IC50 values are shown ± standard deviation, stratified by lowest to highest mean values. (B) Dose-response curves demonstrating the effect of
Lestaurtinib (μM) on cell growth following 72 h of treatment for KMH2, CAL62, THJ-21T (2 biological replicates) and WI-38 (1 biological
replicate) cell lines. (C) Western blot of p-JAK2, JAK2, p-STAT5 and STAT5 showing protein expression of cells that were either untreated or
treated with increasing concentrations (.125–4 μM) of Lestaurtinib, relative to the Staurosporine (St.) control.
https://doi.org/10.1371/journal.pone.0207152.g001
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Fig 2. Treatment of ATC cell lines with Lestaurtinib resulted in an antiproliferative effect, in vitro. (A) Phase contrast images
of WI-38, CAL62 and KMH2 cell lines with and without Lestaurtinib treatment (0.5 μM; 4X magnification). (B) Clonogenic assay
of CAL62 both untreated and treated with increasing concentrations of Lestaurtinib (0.125–4 μM) and stained with 0.5% crystal
violet. Colony formation was quantified by counting colonies from 3 representative fields, with colonies defined as being�50 cells.
(C) Scratch-wound assay of CAL62 cells treated with 0.5 and 4.0 μM Lestaurtinib at 0, 4 and 24 h. Ten measurements were taken
across the width of the scratch and averaged (3 replicates per cell line) per time point. � represents p< 0.05, �� represents p< 0.01,
��� represents p< 0.001, ���� represents p< 0.0001, ns = not significant, Student’s unpaired, two-tail t-test.
https://doi.org/10.1371/journal.pone.0207152.g002
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Fig 3. Treatment with Lestaurtinib resulted in an antiproliferative effect on JAK2 knockout cell lines. (A) Western blot
showing loss of JAK2 expression following JAK2 knockout in CAL62 and KMH2 cell lines and compared to a non-targeting
control. (B) Cellular proliferation of JAK2 knockout cell lines (CAL62 and KMH2) normalized to the non-targeting control
and measured at 72 h. (C) Dose-response curves of CAL62 and KMH2 JAK2 knockout cells following 72 h of treatment with
Lestaurtinib over a 6-point dose range (3 replicates per line). � represents p< 0.05, �� represents p< 0.01, ��� represents
p< 0.001, ���� represents p< 0.0001, ns = not significant, Student’s unpaired, two-tail t-test.
https://doi.org/10.1371/journal.pone.0207152.g003
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PLOS ONE | https://doi.org/10.1371/journal.pone.0207152 November 12, 2018 10 / 16
after 72 h compared to the non-targeting CRISPR control (p = 0.0090)(Fig 3B), while the
KMH2 line demonstrated a significant decrease in cellular proliferation at 72 h compared to
the non-targeting CRISPR control (p = 0.0014)(Fig 3B). Both JAK2 knockout cell lines were
treated with Lestaurtinib over a 6-point concentration range to determine whether Lestaurti-
nib would impact cellular proliferation in the absence of JAK2. We observed a significant
decrease in cellular proliferation of CAL62:JAK2 (KO) at the highest concentration
(p = 0.0060) (Fig 3C). Furthermore, we observed a significant decrease in cellular proliferation
of KMH2:JAK2 KO at every concentration of Lestaurtinib except the lowest (Fig 3C), suggest-
ing that the antiproliferative effect of Lestaurtinib could not be explained solely through a
JAK2 mechanism.
Lestaurtinib treatment did not induce apoptosis, but induced cell cycle
arrest in the G2/M phase
We utilized a live-dead assay of CAL62 and KMH2 cells to determine the effect of Lestaurtinib on
cell health. The number of cells significantly decreased when treated with 1 μM of Lestaurtinib
when compared to the untreated control (p< 0.0001) after 24 h in KMH2 (Fig 4A). Furthermore,
we noted that there was a significant decrease in cell number with both 0.5 (p< 0.0001) and
1.0 μM (p< 0.0001) after 24 h in CAL62 (Fig 4A). There was significant decrease in cell growth
of Lestaurtinib treated KMH2, CAL62 and THJ-21T cell lines at the 72 h for both 0.5 and 4.0 μM
treatments (Fig 4B). Western blot analysis was carried out to determine whether apoptosis was
being induced following Lestaurtinib treatment. At all concentrations, cleaved PARP (c-PARP)
was not detectable, while its presence was detected in cells treated with Staurosporine (St.) as a
positive control (Fig 4C).
As the antiproliferative effects of Lestaurtinib did not appear to result in cell death, we next
evaluated whether Lestaurtinib induced a cytostatic effect on ATC cell lines. CAL62 and
KMH2 cells were treated with a concentration of 4 μM Lestaurtinib for 24 h and this resulted
in a significant decrease in the number of cells in the G1/G0 phase (p = 0.0036) in CAL62 (Fig
4D). An increased number of CAL62 cells in the G2/M phase were also observed; however,
this change was not significant (p = 0.1869) when compared to the vehicle-treated cells (Fig
4D). Lestaurtinib-treated KMH2 cells showed a significant increase in the number of cells in
the G2/M phase (p< 0.0056), and significant decreases in the number of cells in the G1/G0
(p< 0.0022) and S (p = 0.0003) phases (Fig 4D), suggesting a decrease in the proportion of
proliferating cells.
Lestaurtinib restricted tumor growth and exhibited antiangiogenic activity
in an in vivo chick CAM model
The chick CAM model was used to examine the anti-tumor effects of Lestaurtinib in an in vivo
model. CAL62 cells were used to establish xenograft tumors in CAM models. These were
treated with either PBS (vehicle) or Lestaurtinib (4 μM) once a day for 5 days, with drug treat-
ment beginning 2 days post-onplant. Mean endpoint tumor volume of vehicle-treated
embryos (n = 11) was 4.05 ± 1.31 mm3, while that of the Lestaurtinib-treated embryos (n = 19)
was 1.7 ± 1.02 mm3 (p< 0.0001; Fig 5A). Power Doppler ultrasound imaging was used to
determine the inter-group difference in fractional vascular volume at endpoint. Using this
modality, the mean percent vascularity decreased from 23.76 ± 12.95 to 13.99 ± 8.80% with
Lestaurtinib treatment (p = 0.0202; Fig 5B). Together this data suggests that Lestaurtinib may
act as an antiproliferative agent in ATC cell line models and its’ potential as an antiangiogenic
agent warrants further investigation.
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Fig 4. Lestaurtinib exhibited a cytostatic effect on ATC cells, in vitro. (A) Effect of Lestaurtinib (0.5 μM and 1.0 μM) on cell number
following 24 h of treatment (3 replicates per line) for KMH2 and CAL62 cell lines. (B) Growth curves for KMH2, CAL62 and THJ-21T
cell lines following treatment with Lestaurtinib at 0, 24, 48 and 72 h, with 3 technical replicates per timepoint. Statistical analysis is
shown for the 72 h timepoint when compared to the untreated control for the same timepoint. (C) Western blot showing expression of
cleaved PARP (c-PARP) following 24 h of Lestaurtinib doses (0.25–4.0 μM) relative to the apoptosis-inducing Staurosporine (St.)
control. (D) CAL2 and KMH2 cells were treated with Lestaurtinib (4.0 μM) for 24 h (3 replicates per line) prior to BrdU incorporation
and labeling of cells with propidium iodide. A minimum of 10,000 events were counted per test. Proportions of cells within each phase
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of the cell cycle is shown ± standard error. � represents p< 0.05, �� represents p< 0.01, ��� represents p< 0.001, ���� represents p<
0.0001, ns = not significant, Student’s unpaired, two-tail t-test.
https://doi.org/10.1371/journal.pone.0207152.g004
Fig 5. Lestaurtinib exhibits antiproliferative and antiangiogenic activity in the in vivo chick CAM membrane
model. (A) A total of 1 x 106 cells per embryo were administered over top (onplant) of the chick embryo membrane, 9
days post-fertilization. Two days post-onplant, embryos were either treated with the vehicle alone or Lestaurtinib
(4 μM), once daily for 5 days and sacrificed. Mean endpoint tumor volume was measured using ultrasound imaging in
the vehicle-treated (n = 11) and Lestaurtinib-treated (n = 19) embryos. (B) Power Doppler ultrasound imaging
measured the intergroup difference in fractional vascular volume at endpoint to generate mean percent vascularity
between groups. � represents p< 0.05, �� represents p< 0.01, ��� represents p< 0.001, ���� represents p< 0.0001,
ns = not significant, Student’s unpaired, two-tail t-test.
https://doi.org/10.1371/journal.pone.0207152.g005
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Discussion
The aggressive and invasive nature of ATC, paired with the frequency of distant metastases
seen in patients makes this disease very difficult to treat resulting in dismal patient outcomes
[17]. Further, the rarity and rapid progression of this disease are considerable barriers for clini-
cal trials. Thus, preclinical drug development is a crucial step to identify new targeted agents
and the use of cultured cell lines for this purpose remains an important aspect of drug discov-
ery due to their ease of manipulation and ability to test both in vitro and in vivo[7,21].
We identified the tyrosine kinase inhibitor Lestaurtinib as an inhibitor of cellular growth in
ATC cells, with nanomolar IC50’s across the majority of the 13 ATC cell lines tested. Lestaurti-
nib has been previously used in several clinical trials for hematogenous malignancies, but it
has not been explored for potential utility against solid malignancies such as thyroid cancer
[22–25]. Furthermore, it has been studied extensively both in vitro and in vivo, and demon-
strates a highly positive safety record and is orally bioavailable [23,24].
Lestaurtinib has been reported to be a multi-kinase inhibitor, specifically of the JAK2 signaling
pathway[24]; however, many kinase inhibitors have off target effects[26,27], making their true
anti-cancer mechanism unclear. In this study, we have reported the effects of Lestaurtinib in vitro
and in vivo. Although we found evidence that Lestaurtinib did inhibit JAK2 pathway activation
through a concentration-dependent decrease in downstream STAT5 phosphorylation, we also
found that cells with JAK2 knockout demonstrated a similar or increased sensitivity to Lestaurti-
nib, indicating that the antiproliferative effects of Lestaurtinib may be due to off-target effects via
the inhibition of other targets in addition to JAK2. Furthermore, we noted that the antiprolifera-
tive effects of Lestaurtinib were not mediated through apoptosis, but through cell cycle arrest with
the accumulation of drug-treated cells in the G2/M phase of the cell cycle. Further studies are
needed to uncover the true mechanism of action of this drug in addition to JAK2.
Xenografts were developed using the chick CAM model to understand the effects of drug
treatment on tumor volume and vascularity using the CAL62 cell line [28–30]. Our in vivo
studies demonstrated that treatment with Lestaurtinib resulted in a significant reduction in
tumor volume. Furthermore, when we controlled for tumor volume, there was a significant
decrease in the percent tumor vascularity when compared to the vehicle control, demonstrat-
ing a potential antiangiogenic effect that warrants further investigation. Together this data sug-
gests that while Lestaurtinib demonstrates antiproliferative effects in vitro, there is potential
for antiangiogenic effects which contribute to its overall antitumor activity.
In summary, our in vitro and in vivo data suggest that Lestaurtinib may induce its effects
through the inhibition of JAK2 in addition to other off-target effects. Administration of Lestaurti-
nib demonstrated an antiangiogenic effect on ATC tumors, in vivo, with a relatively high drug
dose used as a proof of principle, suggesting that this mechanism of action may be responsible for
the antiproliferative effects observed in our study. Overall, the data in this study suggests that Les-
taurtinib is an effective and valid therapeutic agent in the study of ATC, however, this drug war-
rants further investigation to understand the full potential as a targeted therapy in ATC.
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S1 Table. Short tandem repeat profiling of 13 ATC cell lines. Cell lines were genotyped with
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S1 Fig. Western blot analysis of ATC cell lines to determine endogenous levels of JAK2
and STAT5. Lysates from cell lines that appeared to be sensitive (KMH2, 8505C and BHT-
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